U.S. Viscosupplementation Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

U.S. Viscosupplementation Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

U.S. Viscosupplementation Market size will depict a 7.6% CAGR between 2024 and 2032, owing to strong awareness of viable treatment options for osteoarthritis among patients and healthcare providers across the country. As per the CDC (Centers for Disease Control and Prevention), 1 in 5 adults in the U.S. have some form of arthritis. Rapid advancements in viscosupplementation products has led to the development of higher molecular weight hyaluronic acid (HA) and the introduction of newer and effective formulations. These advancements improve the efficacy and duration of pain relief, making the treatments more attractive to patients and clinicians. The U.S. viscosupplementation industry is classified into product, source of origin, and end-use. By product, the industry size from the 5 injections segment will exhibit a noteworthy CAGR through 2032. With a 5-injection regimen, healthcare providers can tailor treatments to each patient's unique needs, adjusting injection timing and spacing according to individual responses and condition severity. This adaptability has the potential to improve patient outcomes. Compared to single or fewer injections, patients further prefer the 5-injection series as it offers longer-lasting pain relief and enhanced joint function. Based on source of origin, the U.S. viscosupplementation market value from the avian origin segment may record a significant share by 2032. Viscosupplements sourced from avian origins, predominantly rooster combs, boast a high concentration and molecular weight of HA. This characteristic enables them to closely replicate the natural synovial fluid in joints to enhance lubrication and cushioning, which are essential elements in osteoarthritis management. In terms of end-use, the U.S. viscosupplementation industry share from the ambulatory surgical centers segment will register a substantial CAGR from 2024 to 2032. These centers provide greater convenience, reduced wait times, and quicker recovery than conventional hospitals. Viscosupplementation provides a non-surgical option to manage pain and improve joint function, making it attractive for older adults who prefer less invasive treatments. The rising preference for outpatient care and minimally invasive treatments in healthcare will drive segment growth.